Roche's Obesity Drug Helps Almost 87% People Lose At Least 10% Weight

Roche Holdings AG (OTC:RHHBY) on Tuesday released topline results from the CT388-103 Phase 2 trial of CT-388 for obesity.

CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities.

Trial Data

The 469-patient trial was designed to evaluate the efficacy and safety of CT-388 at low, middle, and high doses.

It includes adults with obesity (BMI≥30.0 kg/m2) or overweight (BMI ≥27.0 and <30.0 kg/m2) with at least one weight-related comorbidity without type 2 diabetes, and evaluated five dosing cohorts with different up-titration schemes, with 24mg being the highest dose tested.

The primary endpoint was the percent change in body weight from baseline to week 48.

The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks.

A clear dose-response relationship ...